July 15, 2013 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental new drug application (sNDA) for Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS).

Shore University Medical Center is one of only a handful of hospitals in the country offering the recent U.S. Food and Drug Administration (FDA)-approved Lariat Suture Delivery Device procedure. Electrophysiologists and interventional cardiologists perform this innovative procedure to help prevent stroke in patients who suffer from atrial fibrillation and are unable to take blood thinners.


July 12, 2013 — A Chicago native living in southern California was the first patient at Scripps Health to receive a MitraClip as part of the clinical outcomes assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients (COAPT) trial.

July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer coronary stent system. The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events.

In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation has entered into a definitive agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, for $275 million in cash. The company expects to close the transaction in the second half of 2013, subject to customary closing conditions.

Aspirin has been widely used for more than 50 years as a common, inexpensive blood thinner for patients with heart disease and stroke, but doctors have little understanding of how it works and why some people benefit and others do not.

Abiomed’s Impella percutaneous left ventricular assist device (pLVAD) was recently deployed at Baylor Medical Center in McKinney, Texas, to treat country music singer Randy Travis.

Sudden cardiac death (SCD) is the leading cause of death in high school-aged athletes. To determine if SCD can be prevented with a heart screening, The Christ Hospital Health Network (Cincinnati, Ohio), The University of Mississippi Medical Center and Cincinnati Children’s Hospital Medical Center partnered with USRowing and Toshiba America Medical Systems Inc. to conduct The Athlete Heart Research Study. Initial participants included volunteer high school rowers with more than two years of continuous practice who competed in the USRowing Youth National Championships, June 7 – 9, 2013 in Oak Ridge, Tenn.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now